Racial differences in comorbidity profile among patients with chronic obstructive pulmonary disease

Hyun Lee1, Sun Hye Shin2, Seonhye Gu3, Di Zhao3, Danbee Kang3,4, Yeong Rae Jo3, Gee Young Suh2, Roberto Pastor-Barriuso6, Eliseo Guallar4,5, Juhee Cho3,4,5* and Hye Yun Park2†

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is often accompanied by multiple comorbidities, which are associated with an increased risk of exacerbation, a poor health-related quality of life, and high mortality. However, differences in comorbidity profile by race and ethnicity in COPD patients have not been fully elucidated.

Methods: Participants aged 40 to 79 years with spirometry-defined COPD from the U.S. National Health and Nutrition Examination Survey (NHANES) (2007–2012) and from the Korea NHANES (2007–2015) were analyzed to compare the prevalence of comorbidities by race and ethnicity group. Comorbidities were defined using questionnaire data, physical exams, and laboratory tests.

Results: Non-Hispanic Whites had the highest prevalence of dyslipidemia (65.5%), myocardial infarction (6.2%), osteoarthritis (40.1%), and osteoporosis (13.6%), while non-Hispanic Blacks had the highest prevalence of asthma (24.0%), hypertension (70.2%), stroke (7.3%), diabetes mellitus (DM) (23.3%), anemia (16.4%), and rheumatoid arthritis (11.9%). Compared to non-Hispanic Whites, non-Hispanic Blacks had a significantly higher prevalence of hypertension, stroke, DM, anemia, and rheumatoid arthritis after adjusting for age, sex, body mass index, and smoking status, while Hispanics had a significantly higher prevalence of DM and anemia, and Koreans had significantly lower prevalences of all comorbidities except stroke, DM, and anemia.

Conclusions: COPD-related comorbidities varied significantly by race and ethnicity, and different strategies may be required for the optimal management of COPD and its comorbidities in different race and ethnicity groups.

Keywords: COPD, Comorbidity, Race, Ethnicity

Background

Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterized by persistent respiratory symptoms and airflow limitations [1]. Due to the ongoing epidemic of smoking and to prolonged life expectancy, COPD is projected to increase in prevalence and to contribute over 4.5 million annual deaths worldwide by 2030 [2, 3].

Since aging and smoking are independent risk factors not only for COPD, but also for multiple chronic diseases, COPD is often accompanied by comorbidities, including cardiovascular disease (CVD), osteoporosis, metabolic syndrome, depression, and several types of cancer [4]. Furthermore, in COPD patients, these comorbidities are associated with an increased risk of exacerbation [5], a poor health-related quality of life [6], increased utilization of health services [7], and high mortality [8]. As a consequence, recent COPD guidelines give special emphasis to the management of comorbid conditions in COPD [1].

COPD guidelines, however, have been developed using data primarily from populations of European descent. COPD and associated comorbidities have multiple genetic, behavioral, environmental, and socioeconomic risk factors, which may vary substantially across racial
groups, like other diseases [9–11], but differences in comorbidity profile by race and ethnicity in COPD patients have not been fully elucidated. This study aimed to evaluate differences in comorbidity profile by race and ethnicity in subjects with COPD participating in nationally representative surveys from the United States and South Korea.

**Methods**

**Participants**

We used data from the 2007–2012 cycles of the U.S. National Health and Nutrition Examination Survey (NHANES) and from the 2007–2015 cycles of the Korea NHANES (KNHANES). Both surveys provide nationally representative data of the non-institutionalized population using a multi-stage cluster sampling design. We restricted our analysis to men and women 40 to 79 years old with spirometry-defined COPD [pre-bronchodilator forced expiratory volume in 1 s (FEV₁) / forced vital capacity (FVC) < 70%] [12]. Among U.S. NHANES participants, we further restricted the analysis to those who self-identified as Non-Hispanic White (n = 944), Non-Hispanic Black (n = 324), or Hispanic (n = 227). KNHANES provided a representation of Asians (n = 3808), as the number of Asian participants with COPD in U.S. NHANES was too small for comparisons (Fig. 1).

**Spirometric measurement**

In both surveys, spirometry was performed according to the recommendations of the American Thoracic Society and European Respiratory Society [13]. Absolute values of FEV₁ and FVC were obtained, and the percentage of predicted values for FEV₁ and FVC were calculated using the reference equation obtained from an analysis of the general U.S. population for U.S. NHANES [14] and a representative Korean sample for KNHANES [15].

**Definitions**

COPD was defined based on pre-bronchodilator FEV₁ / FVC < 0.7, and COPD severity was classified as mild (FEV₁ ≥ 80% predicted), moderate (50% ≤ FEV₁ < 80% predicted), or severe-to-very severe (FEV₁ < 50% predicted) [1]. Height and weight were measured and body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Obesity was defined as BMI ≥ 30.0 kg/m² and overweight was defined as BMI = 25.0–29.9 kg/m² in Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanics, and as BMI ≥ 25 kg/m² for obesity and as BMI = 23.0–24.9 for overweight in Koreans according to World Health Organization guidelines [16].

Comorbidities were defined as a self-reported physician diagnosis. In addition, hypertension was defined as the use of antihypertensive medication, a systolic
blood pressure ≥ 140 mmHg, or a diastolic blood pressure ≥ 90 mmHg. Dyslipidemia was defined as the use of lipid-lowering medications or a low-density lipoprotein cholesterol level greater than 130 mg/dL or high-density lipoprotein cholesterol level less than 40 mg/dL [17]. Diabetes mellitus (DM) was defined as the use of glucose-lowering medications or a fasting plasma glucose level ≥ 126 mg/dL. Anemia was defined as hemoglobin level < 13 g/dL in men and < 12 g/dL in women [18].

Outcomes
We compared the comorbidity profile by race and ethnicity in subjects with COPD participating in U.S. and Korea NHANES. As comorbidities, we included asthma, hypertension, dyslipidemia, stroke, myocardial infarction, DM, and osteoporosis, which were recommended for screening and management in the Global Initiative for COPD guideline [1], plus anemia, osteoarthritis, and rheumatoid arthritis (RA), three common conditions having a substantial impact on the quality of life.

Statistical analysis
Statistical analysis used the svy commands in Stata (release 13.1; StataCorp LP, College Station, TX, USA) to account for survey weights and for the complex sampling design. For each comorbidity, we calculated its prevalence and 95% confidence interval (CI) by race and ethnicity group and used log binomial regression to estimate adjusted prevalence ratios (aPRs) and 95% CIs comparing each race and ethnicity group to Non-Hispanic Whites, adjusting for age, sex, BMI, and smoking status.

Table 1 Characteristics of participants with COPD aged 40–79 by race and ethnicity, U.S. NHANES 2007–2012 and Korea NHANES 2007–2015

|                      | U.S. NHANES |                      |                      | Korea NHANES |                      | p value |
|----------------------|-------------|----------------------|----------------------|--------------|----------------------|---------|
|                      | Non-Hispanic White (n = 944) | Non-Hispanic Black (n = 324) | Hispanic (n = 227) | Korean (n = 3808) |                      |         |
| **Age, years**       |             |                      |                      |              |                      |         |
| Age group, years     |             |                      |                      |              |                      |         |
| 40–49                | 18.7 (1.7)  | 20.7 (2.9)           | 19.7 (3.1)           | 11.3 (0.7)   |                      | < 0.001 |
| 50–59                | 31.2 (2.2)  | 30.9 (2.6)           | 29.9 (3.9)           | 23.2 (0.9)   |                      |         |
| 60–69                | 30.3 (2.4)  | 24.1 (1.8)           | 32.0 (3.0)           | 31.2 (0.9)   |                      |         |
| 70–79                | 19.8 (1.3)  | 24.2 (2.5)           | 18.3 (2.7)           | 34.3 (1.0)   |                      |         |
| **Men, %**           |             |                      |                      |              |                      | < 0.001 |
| BMI, kg/m²           |             |                      |                      |              |                      | 0.023   |
| Underweight          | 1.9 (0.5)   | 3.1 (1.2)            | 0                    | 2.7 (0.4)    |                      |         |
| Normal               | 32.3 (1.6)  | 35.1 (2.8)           | 27.4 (3.4)           | 38.9 (1.1)   |                      |         |
| Overweight           | 37.8 (1.5)  | 33.4 (2.3)           | 41.9 (3.7)           | 27.6 (0.9)   |                      |         |
| Obese                | 27.9 (1.4)  | 28.4 (2.6)           | 30.7 (3.8)           | 30.7 (1.0)   |                      |         |
| **Smoking**          |             |                      |                      |              |                      | < 0.001 |
| Current              | 33.5 (2.4)  | 42.4 (3.4)           | 26.4 (2.8)           | 41.6 (1.0)   |                      |         |
| Former               | 39.9 (2.1)  | 26.4 (2.2)           | 35.5 (2.9)           | 27.9 (0.9)   |                      |         |
| Never                | 26.6 (2.1)  | 313 (2.8)            | 381 (3.3)            | 30.5 (1.0)   |                      |         |
| **Spirometry**       |             |                      |                      |              |                      |         |
| FVC, % predicted     | 96.5 (0.7)  | 96.7 (1.1)           | 97.9 (1.4)           | 90.5 (0.3)   |                      | < 0.001 |
| FEV₁, % predicted    | 80.3 (0.7)  | 77.5 (1.1)           | 82.6 (1.3)           | 77.8 (0.3)   |                      | < 0.001 |
| **COPD severity**    |             |                      |                      |              |                      | 0.106   |
| Mild                 | 52.3 (2.3)  | 46.5 (3.1)           | 60.4 (4.1)           | 46.4 (1.0)   |                      |         |
| Moderate             | 41.3 (2.2)  | 44.4 (3.1)           | 36.0 (4.3)           | 48.7 (1.1)   |                      |         |
| Severe-to-very severe| 6.4 (0.8)   | 9.2 (2.3)            | 3.6 (1.1)            | 4.9 (0.4)    |                      |         |

*pValues are presented as weighted means (standard error of the mean) or weighted percentage (standard error of the percentage)

*Hispanic was defined as Mexican American or other Hispanic

Participants were categorized as having mild (FEV₁ / FVC < 0.7 and FEV₁ ≥ 80% predicted), moderate (FEV₁ / FVC < 0.7 and 50% ≤ FEV₁ < 80% predicted), or severe-to-very severe (FEV₁ / FVC < 0.7 and FEV₁ < 50% predicted) disease based on the Global Initiative for Chronic Obstructive Lung Disease guideline COPD chronic obstructive pulmonary disease, NHANES National Health and Nutrition Examination Survey (NHANES), BMI body mass index, FEV₁ forced expiratory volume in 1 s, FVC forced expiratory vital capacity
Results
The average age of non-Hispanic Whites, non-Hispanic Blacks, and Hispanics was similar (59.8, 59.6, and 59.6 years, respectively), but Koreans were older on average (63.6 years, \( p < 0.001 \); Table 1). By sex, the proportions of men among non-Hispanic Whites and non-Hispanic Blacks were similar (59.1 and 60.2%, respectively), and lower than among Hispanic (69.2%) and Korean (73.8%) participants. Hispanic participants were the most likely to be overweight or obese (72.6%), while Non-Hispanic Blacks and Koreans were the most likely to be current smokers (42.4 and 41.6%, respectively). By severity, non-Hispanic Blacks had the highest proportion of severe-to-very-severe COPD (9.2%), while Hispanics had the lowest (3.6%).

Non-Hispanic White participants had the highest prevalence of dyslipidemia (65.5%), myocardial infarction (6.2%), osteoarthritis (40.1%), and osteoporosis (13.6%), while non-Hispanic Blacks had the highest prevalence of asthma (24.0%), hypertension (70.2%), stroke (7.3%), DM (23.3%), anemia (16.4%), and RA (11.9%) (Table 2 and Fig. 2). Hispanics had very high prevalences of all comorbidities except for stroke, ranking second in the prevalence of asthma, hypertension, myocardial infarction, DM, anemia, RA, and osteoporosis compared to other race and ethnicity groups. Koreans had the lowest prevalence of all comorbidities except for stroke, DM, and anemia.

Compared to non-Hispanic Whites, non-Hispanic Black participants had a significantly higher prevalence of hypertension (aPR 1.36, 95% CI 1.23 to 1.51), stroke (aPR 2.01, 95% CI 1.16 to 3.47), DM (aPR 1.76, 95% CI 1.34 to 2.31), anemia (aPR 3.82, 95% CI 2.42 to 6.04), and RA (aPR 1.83, 95% CI 1.16 to 2.89) after adjusting for age, sex, BMI, and smoking status, while Hispanics had a higher prevalence of DM (aPR 1.64, 95% CI 1.18 to 2.29) and anemia (aPR 2.18, 95% CI 1.23 to 3.86). Koreans had significantly lower prevalences of all comorbidities except stroke, DM, and anemia (Table 3).

Discussion
We found major differences in the comorbidity profile among race and ethnicity groups in subjects with COPD. Non-Hispanic Whites had a comorbidity pattern characterized by dyslipidemia, myocardial infarction, osteoarthritis, and osteoporosis. Non-Hispanic Blacks had a high prevalence of current smokers as well as a high prevalence of multiple comorbidities, especially asthma, hypertension, stroke, DM, anemia, and RA. Hispanics had the highest average BMI levels, as well as high prevalences of asthma and DM. Finally, Koreans had the highest prevalence of current smokers, but lower prevalences of other comorbidities except for stroke, DM, and anemia. Given that coexisting comorbidities have an adverse impact on COPD prognosis, early recognition and management of prevalent disease based on racial differences could reduce the clinical burden of disease in COPD patients.

CVD is a key comorbidity in COPD patients and a major determinant of mortality and functional status [19]. In our study, non-Hispanic Whites had a pattern of CVD comorbidities characterized by a high prevalence of dyslipidemia and coronary disease, while non-Hispanic Blacks had a pattern driven by hypertension, DM, and stroke. These were like the results of a previous study that compared COPD...
comorbidities between non-Hispanic Whites and non-Hispanic Blacks [20]. In comparison, Hispanics had a pattern driven by obesity and DM. In addition to CVD, asthma is a major comorbidity as well as a risk factor in COPD, complicating treatment and further impairing functional status. Asthma prevalence was particularly high among non-Hispanic Blacks, although non-Hispanics Whites and Hispanics also had a relatively high prevalence. Considering their high prevalence and disease burden, clinicians should consider active screening and management of CVD and asthma in COPD patients.

Anemia has recently been recognized as an independent prognostic predictor of increased hospitalization and mortality in COPD [21–24]. It is also an important comorbidity linked to nutritional deficiency and poor exercise performance among COPD patients [23]. Previous studies have suggested the possibility of improving functional outcomes by correcting anemia [25, 26], and active screening and management of anemia among COPD patients may be beneficial for clinical outcomes, especially among non-Hispanic Blacks and Hispanics.

Non-Hispanic Blacks had very high prevalences of COPD risk factors and comorbidities. Multiple sources of health disparities and inequalities, including socioeconomic factors, environmental hazards, behavioral factors, and access to health care and preventive services, contribute to the excess burden of disease and mortality among non-Hispanic Blacks in the U.S. [27]. The presence of multiple comorbidities may further complicate management and prognosis in these patients [28, 29]. It may be necessary, however, to develop integrated approaches to prevention and management to reduce the burden of chronic disease-related morbidity and mortality, particularly among non-Hispanic Black subjects with COPD.

![Fig. 2 Prevalence of comorbidities among participants with COPD aged 40–79 by race and ethnicity, U.S. NHANES 2007–2012 and Korea NHANES 2007–2015. COPD chronic obstructive pulmonary disease, NHANES National Health and Nutrition Examination Survey](image-url)
Hispanic subjects with COPD had a very high burden of overweight and obesity and DM, although the prevalence of myocardial infarction was lower than in non-Hispanic Whites. The lower prevalence of CVD, despite relatively high levels of metabolic risk factors among Hispanics, has been termed the Hispanic paradox [30], but the reasons for this paradox are controversial. Irrespective of the implications of elevated BMI in Hispanic patients, the high prevalence of overweight and obesity in this group should prompt proper management, as morbid obesity is a risk for poor management and functional decline in COPD [31, 32].

Finally, although Korean COPD patients were older, more likely to be smokers, and more likely to be male than other race or ethnicity groups, they had the lowest prevalences of most comorbidities. A similar pattern has been observed in other Asian countries [33]. In particular, the low prevalence of myocardial infarction in Koreans may reflect lower background rates of the disease due to environmental or genetic factors. Since smoking is a predominant risk factor for COPD among Asians and considering the increasing number of Asians in the U.S., more active surveillance regarding COPD and its comorbidities may be warranted.

Several limitations need to be considered when interpreting our findings. First, we used a cross-sectional study and we do not have information on the timing of the development of each comorbidity. We were, thus, unable to establish causal inferences. Our objective, however, was to compare the comorbidity patterns across race and ethnicity groups, not to identify causal pathways of comorbidities. The different comorbidity patterns may be due to different prevalences of risk factors such as smoking, obesity, socioeconomic status, or environmental exposures, but race and ethnicity may affect the development of comorbidities. Second, we could not evaluate the prevalence of some important COPD-related comorbidities or conditions, such as obstructive sleep apnea or use of long-term oxygen therapy, due to lack of data in either U.S. NHANES or KNHANES. Third, we did not have data that would allow us to evaluate the outcomes of the different comorbidities. This information is important for understanding the impact of the differences in comorbidity profile by race and ethnicity. Given the racial differences in outcomes such as emergency room visits and duration of hospital stays [7], further studies should evaluate the management and outcomes of COPD, including exacerbations and mortality, by comorbidity profile. Fourth, we used data for Koreans as we did not have data for other Asian groups. However, Korean COPD patients had similar overall characteristics as other Asian COPD patients, including Taiwanese, Japanese, or Chinese patients, although the degree of exposure to biomass fuels differed across Asian groups [33].

**Conclusions**

In our study, COPD-related comorbidities occurred disproportionately according to race and ethnicity, and different strategies may be required for the optimal management of COPD and its comorbidities for different race and ethnicity groups. Furthermore, the generation of local maps of COPD-related comorbidities may help in planning different strategies for the diagnosis, treatment, and prevention of COPD and its associated comorbidities.
Abbreviations

aPR: adjusted prevalence ratio; BMI: body mass index; CI: confidence interval; COPD: chronic obstructive lung disease; CVD: cardiovascular disease; DM: diabetes mellitus; FEV 1: forced expiratory volume in 1 s; FVC: forced vital capacity; KNHANES: Korea National Health and Nutrition Examination Survey; NHANES: National Health and Nutrition Examination Survey; RA: rheumatoid arthritis

Availability of data and materials

All data extracted in this study are included in this article.

Funding

Not applicable.

Acknowledgements

Not applicable.

Authors’ contributions

HL, JC, and HYP were responsible for the conception and design of the study. HL, SS, SG, JC, and HYP conducted the experiments and data acquisition. HL, SS, SG, DZ, DK, YRI, GYS, RP, EG, JC, and HYP undertook the analysis and interpretation of the data. HL, SG, EG, JC, and HYP drafted the manuscript. HL, SS, SG, DZ, DK, YRI, GYS, RP, EG, JC, and HYP made a critical revision of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

As we used publicly available data, our institutions waived the need for ethical approval. The original U.S. NHANES and KNHANES surveys we used were approved by the relevant institutional review boards and all participants provided written, informed consent.

Consent for publication

Not applicable.

Competing interests

HYP has received lecture fees from AstraZeneca, Novartis, and Boehringer-Ingelheim. HL, SHS, SG, DZ, DK, YRI, GYS, RP, EG, and JC have no competing interests to declare.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea.
2Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
3Center for Clinical Epidemiology, Samsung Medical Center, Seoul, South Korea.
4Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.
5Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
6National Center for Epidemiology, Instituto de Salud Carlos III, and Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.

Received: 13 January 2018 Accepted: 22 August 2018
Published online: 04 October 2018

References

1. GOLD. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (2018 Report) Available from www.goldcopd.org. Accessed 1 June 2018.
2. Lopez AO, Shibuya K, Rao C, Mathers CD, Ezzati M, Jamison DT, et al. Global and regional burden of disease and risk factors, 2001-2010: systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9838):206–14. Review.
3. World Health Organization. Mortality and causes of death, 2015 and 2030. Available at: http://www.who.int/healthinfo/global_burden_disease/projections/en/. Assessed 1 June 2018.

4. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruinzeel PL, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;187:728–35.
5. Westerik JA, Metting EL, van Boven JF, Tienstra W, Kocks JW, Schermer TR. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res. 2017;18:31.
6. Huber MB, Wacker ME, Vogelmeier CF, Leidl R. Comorbid influences on generic health-related quality of life in COPD: a systematic review. PLoS One. 2015;10:e0132670.
7. Westney G, Foreman MG, Xu J, Henriquez King M, Flenbaugh E, Rust G. Impact of comorbidities among Medicaid enrollees with chronic obstructive pulmonary disease, United States, 2009. Prev Chronic Dis. 2017;14:E31.
8. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28:1245–57.
9. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006;354:333–42.
10. Bahrami H, Krommal R, Bluemke DA, Olson J, Shea S, Liu K, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168:2138–45.
11. Gutierrez J, Williams OA. A decade of racial and ethnic stroke disparities in the United States. Neurology. 2014;82:1080–2.
12. Lange P, Celli B, Agusti A, Boje Jensen G, Divo M, Faner R, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373:111–22.
13. Miller MR, Hinkson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.
14. Hinkson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179–87.
15. Choi JK, Paek D, Lee JO. National prevalence of anemia in the population: Tuberc. Respir Dis. 2005;56:320–42.
16. WHO. Physical Status: The use and interpretation of anthropometry: report of a World Health Organization (WHO) expert committee. Geneva: World Health Organization; 1995.
17. Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2016;316:1997–2007.
18. World Health Organization. Haemoglobin concentrations for the diagnosis of Anaemia and assessment of severity, Vitamin and mineral nutrition information system. Geneva: World Health Organization; 2011. Available from: http://www.who.int/vmnis/indicators/haemoglobin.pdf. Accessed 1 July 2018.
19. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardio-mortality and morbidity. Thorax. 2005;50:28–31.
20. Putcha N, Han MK, Martinez CH, Foreman MG, Anzueto AR, Casaburi R, et al. Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans. Chronic Obstr Pulm Dis. 2014;1:105–14.
21. Chambellan A, Chailleux E, Similowski T. Prognostic value of the hemocrit in patients with severe COPD receiving long-term oxygen therapy. Chest. 2005;128:1201–8.
22. Martinez-Rivera C, Portillo K, Munoz-Ferrer A, Martinez-Ortiz ML, Molins E, Serra P, et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD. 2012;9:423–50.
23. Oh YM, Park JH, Kim EK, Hwang SC, Kim HJ, Kang DR, et al. Anemia as a clinical marker of stable chronic obstructive pulmonary disease in the Korean obstructive lung disease cohort. J Thorac Dis. 2017;9:5008–16.
24. Park SC, Kim YS, Kang YA, Park EC, Shin CS, Kim DW, et al. Hemoglobin and mortality in patients with COPD: a nationwide population-based cohort study. Int J Chron Obstruct Pulmon Dis. 2018;13:1599–605.
25. Schonhofer B, Wenzel M, Geibel M, Kohler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med. 1998;26:1624–8.
26. Silverberg DS, Mor R, Weu MT, Schwartz D, Schwartz FJ, Chernin G. Anemia and iron deficiency in COPD: patients' prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med. 2014;14:2/4.
27. Centers for Disease Control and Prevention. CDC Health Disparities and Inequalities Report — United States, 2013. https://www.cdc.gov/mmwr/pdf/other/su6203.pdf. Accessed 1 June 2018.
28. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1:73–83.
29. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95–109.
30. Rodriguez CJ, Allison M, Daviglus ML, Isasi CR, Keller C, Leira EC, et al. Status of cardiovascular disease and stroke in Hispanics/Latinos in the United States: a science advisory from the American Heart Association. Circulation. 2014;130:593–625.
31. O'Donnell DE, Ciavaglia CE, Neder JA. When obesity and chronic obstructive pulmonary disease collide: Physiological and clinical consequences. Ann Am Thorac Soc. 2014;11:635–44.
32. Katz P, Irbarren C, Sanchez G, Blanc PD. Obesity and functioning among individuals with chronic obstructive pulmonary disease (COPD). COPD. 2016; 13:352–9.
33. Oh YM, Bhome AB, Boonsawat W, Gunasekera KD, Madagedara D, Idolor L, et al. Characteristics of stable chronic obstructive pulmonary disease patients in the pulmonology clinics of seven Asian cities. Int J Chron Obstruct Pulmon Dis. 2013;8:31–9.